About Technology Pipeline & Clinical Trials Patients & Families Newsroom CONTACT US Dedicated to making life better for people suffering from rare diseases with few or no treatment options LEARN MORE We are focused on developing disease-modifying therapies that address unmet medical needs of patients and families suffering from rare diseases with the goal of making a positive difference in their lives. Matthew Gantz, President and Chief Executive Officer Our robust development pipeline of personalized, targeted and redosable therapies Leveraging our proprietary, autologous fibroblast technology platform Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB) Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the Oliveira family. Used with permission. Gene Therapy for Localized Scleroderma Courtesy of the Scleroderma Foundation and Kaylee Renee’s family. Used with permission. What's New Castle Creek Biosciences, Inc. 405 Eagleview Boulevard Exton, PA 19341 484.713.6000 Connect with us: ©2021 Castle Creek Biosciences, Inc. All Rights Reserved. The registered dual crescent logo and “Castle Creek Biosciences” are trademarks of Castle Creek Biosciences, LLC. Privacy Policy | Terms of Use